Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment1.41%-1.27 ppPharmaceuticals3.06%-1.12 ppManaged Health Care0.51%-1.01 ppBiotechnology1.45%-0.69 ppLife Sciences Tools & Services0.65%-0.44 ppHealth Care Services0.31%-0.22 ppHealth Care Distributors0.33%-0.10 ppHealth Care Facilities0.15%-0.05 ppHealth Care Supplies0.06%-0.04 ppHealth Care Technology0.02%-0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.45%
Industry change · 12M
-0.69 pp
Biotechnology · contribution
-0.690 pp
Company participation
13%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Mar 2026 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $384.6bn | 0.560% | -0.231 pp | -0.318 pp | +7.3% | No |
| Vertex Pharmaceuticals → VRTX | United States | $113.4bn | 0.165% | -0.060 pp | -0.130 pp | -7.9% | No |
| Amgen → AMGN | United States | $189.7bn | 0.276% | -0.069 pp | -0.121 pp | +16.5% | No |
| Gilead Sciences → GILD | United States | $173.0bn | 0.252% | -0.046 pp | -0.079 pp | +27.7% | No |
| Regeneron Pharmaceuticals → REGN | United States | $72.6bn | 0.106% | -0.036 pp | -0.036 pp | +22.5% | No |
| Biogen → BIIB | United States | $26.9bn | 0.039% | -0.011 pp | -0.008 pp | +34.0% | No |
| Moderna → MRNA | United States | $20.1bn | 0.029% | +0.007 pp | +0.003 pp | +79.2% | Yes |
| Incyte → INCY | United States | $18.7bn | 0.027% | -0.011 pp | -0.001 pp | +55.4% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.